Moberg Pharma AB (publ) (MOB) Q1 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Moberg Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.835 Good afternoon and welcome to the Moberg Pharma telephone conference. 00:00:03.835 -- 00:00:06.918 My name is Charlie and I'll be coordinating the call today. 00:00:06.918 -- 00:00:11.002 If you'd like to ask a question at the end of the presentation you can do so by pressing 00:00:11.002 -- 00:00:14.506 star 5 by 1 on the telephone keypad. 00:00:14.506 -- 00:00:17.769 I will now hand over to our host Anna Young, CFO, to begin. 00:00:17.769 -- 00:00:20.730 Anna, please go ahead. 00:00:20.892 -- 00:00:26.238 Thank you and welcome to this telephone conference following the press release this morning. 00:00:26.238 -- 00:00:31.348 And this call will be recorded and uploaded on our webpage following 00:00:31.348 -- 00:00:36.760 completion. So with me today, I have our Chief Medical Officer Anders Bredesen 00:00:36.760 -- 00:00:41.429 and our Chief Scientific Officer Amir Tavakol. 00:00:41.429 -- 00:00:45.978 And before opening up for questions, I would like to provide a short summary on the information 00:00:45.978 -- 00:00:48.243 that we received this morning. 00:00:48.243 -- 00:00:53.748 So in essence, we received information about clinical cure in a subset 00:00:53.748 -- 00:00:59.013 of patients for our North American phase 3 study for MOB15 against 00:00:59.013 -- 00:01:00.674 onychomycosis. 00:01:00.674 -- 00:01:05.919 And the number of patients who have achieved clinical cure in this blinded subset 00:01:05.919 -- 00:01:09.602 of patients is lower than our expectations. 00:01:09.602 -- 00:01:14.507 And clinical cure, that's the sufficient assessment of the amount of affected nail area 00:01:14.507 -- 00:01:18.753 for a patient. For clinical cure, this has to be zero. 00:01:18.753 -- 00:01:23.459 you are perfectly healthy looking ...